{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-009063","form_type":"8-K","ticker":"RVPH","cik":"0001742927","company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","filed_at":"2026-03-19T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.052554+00:00","generated_at":"2026-05-15T09:39:14.940475+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Reviva Pharmaceuticals announces $10M public offering of stock and warrants","bullets":["Offering of 6,666,667 shares (or pre-funded warrants) plus Series G and H warrants at $1.50/unit; gross proceeds $10M.","Series G warrants exercisable at $1.50 for 5 years; Series H warrants exercisable at $1.50 for 1 year.","Net proceeds ~$9M to fund RECOVER-2 Phase 3 trial for brilaroxazine in schizophrenia and for working capital.","Closing expected March 20, 2026; A.G.P./Alliance Global Partners acting as sole placement agent."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-009063","json":"https://secwatch.observer/filing/0001437749-26-009063.json","markdown":"https://secwatch.observer/filing/0001437749-26-009063.md","text":"https://secwatch.observer/filing/0001437749-26-009063.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1742927/000143774926009063/0001437749-26-009063-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1742927/000143774926009063/rvph20260319_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T09:39:14.940475+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e68ca321d7c3688094aac85581b55a34d923f066","claim":"REVIVA PHARMACEUTICALS HOLDINGS, INC. entered into Placement Agency Agreement with A.G.P./Alliance Global Partners valued at 7.0% of the aggregate gross proceeds (effective 2026-03-18).","evidence_excerpt":"the Company entered into a placement agency agreement (the “Placement Agency Agreement”), dated March 18, 2026, with A.G.P./Alliance Global Partners (the “Placement Agent”) pursuant to which the Company agreed to pay the Placement Agent a total cash fee equal to 7.0% of the aggregate gross proceeds of the Offering","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1742927/000143774926009063/0001437749-26-009063-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"A.G.P./Alliance Global Partners"},{"label":"Value","value":"7.0% of the aggregate gross proceeds"},{"label":"Effective","value":"2026-03-18"}]},{"claim_id":"ff203614192e6d98dabd687538fae538ee1dee2e","claim":"REVIVA PHARMACEUTICALS HOLDINGS, INC. entered into Purchase Agreement with certain institutional investors valued at $10.0 million (effective 2026-03-18).","evidence_excerpt":"On March 18, 2026, Reviva Pharmaceuticals Holdings, Inc. (the “Company”) entered into agreements, including a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors, pursuant to which the Company agreed to sell and issue, in a registered public offering (the “Offering”), (i) an aggregate of 6,283,334 shares (the “Shares”) of the Company’s common stock","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1742927/000143774926009063/0001437749-26-009063-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain institutional investors"},{"label":"Value","value":"$10.0 million"},{"label":"Effective","value":"2026-03-18"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}